Junko Saber and I started Innopiphany with the goal of creating a unique service-oriented consulting group that would give our customers greater flexibility and superb insights quickly. Each of us has been working in life sciences since 1994 with 14 years related consulting experience. Our goal is to give you, our future customer, excellence and acumen in every thing we deliver to make your journey with us effortless.
-Lisa Kennedy, Founder
Lisa Kennedy, Managing Principal
Dr. Lisa Kennedy specializes in strategy, new business model innovation, marketing, market access, macroeconomic health analysis and commercialization. Dr. Kennedy headed and grew the UK arm of the health economics and market access company, The Lewin Group (UK) (Quintiles’ consulting arm now owned by United Healthcare) to a $3M business. She was the UK Managing Director and an Officer of the first pan-European consumer and provider eHealth company, Planet Medica and made the 2000 Financial Times Top-10 Digital Management Teams. In 2005, Dr. Kennedy joined GE Healthcare as Chief Economist and received the CEO’s President Award for creating a team to drive thought-leadership with 100 publications demonstrating how GE Healthcare products and services make a strong impact on patient outcomes and cost-effectiveness. She then held the role of Global Head of Marketing Operations for GE Healthcare’s 1500-strong marketing organization, where she managed the innovation portfolio of over 200 products and services; and led GE Healthcare’s strategy (Growth Playbook) during which the company grew $2B. In 2009 she was awarded the GE Vice Chairman’s Award from John Rice for the creation and launch of GE’s $6B healthymagination innovation incubator and corporate garage. She then went on to become the Chief Marketing Officer for healthymagination where she led innovation including consumer health incubation and strategic marketing including all branding efforts.
Junko Saber, Managing Principal
Junko Saber has over 20 years of life sciences experience, with the past 10 years in life sciences management consulting. She is an expert in business model evolution, forecasting and market entry and geographic expansion commercialization strategies. Junko’s experience ranges across a variety of therapeutic areas, including, but not limited to rare diseases, oncology, immunology and endocrinology. Prior to Innopiphany, Junko worked as a Managing Principal at the Mirubi Group LLC and as a Senior Consultant at The Frankel Group (acquired by Huron in 2014). She also spent a decade working in industry at Merck, Genzyme and Abbott Laboratories, where she held various positions in project management, clinical development, resource and research planning and regulatory affairs. Junko holds an MBA from New York University and Bachelor Degrees in Chemistry and Japanese from the University of California at Berkeley.
Mahmoud Adham, Principal
Mahmoud Loghman-Adham, MD is a pediatric nephrologist by training, currently a consultant to pharmaceutical and biotech industry. Most recently, he was a Medical Director at Baxalta (now part of Shire), in Westlake Village, California. He provides strategic medical and scientific advice on clinical trial design and execution and on business development, including due diligence for new molecules to treat orphan diseases. Prior to joining Baxalta, he was a Senior Medical Director and a Translational Medicine Leader at Hoffmann-La Roche Inc, starting in 2001. He has led clinical trials from Phase 2 to 4 in anemia, renal diseases, inflammatory and autoimmune diseases, emphysema/COPD, and hematology /oncology. He has worked on biomarker identification and selection and their incorporation into proof-of-concept clinical trials. His areas of interest include chronic kidney disease, nephrotoxicity, inflammatory/auto-immune diseases and pulmonary diseases.
Susan Haynie, Principal
Dr. Susan Haynie is a Data Scientist and Applied Demographer specializing in custom geospatial, demographic and data analytics services. She creates unique research approaches by incorporating cross-industry experience and advanced skills in Alteryx (a leading data science, big data and machine learning platform). She has demonstrated success working in multiple industries including healthcare, retail, utilities, and entertainment. She is an expert in business information evaluation and acquisition, data cleansing, formatting of large unstructured datasets to reveal new information, and statistical and mathematical modeling. Highlights of her work include identifying high-priority, at-risk consumers by analyzing sales data for a major medical organization; estimating health care and insurance-potential models for the elderly population based on geo-demographics and survey response patterns; developing models of age-specific fertility / mortality rates for China accounting for variations in the one-child policy and migrant population flows by region; and, following the 2008 Sichuan, China earthquake, calculating affected population counts and locating health facilities by varying levels of earthquake intensity, improving response time and resource mobilization for life-saving relief organizations including the IFRC. Dr. Haynie was awarded a National Institute of Health SBIR (Small Business Innovation Research) grant –- “Small Area Demographic Estimates for China with Remote Sensing, GIS and Spatial Modeling.” She is a published author and has presented at conferences in the USA and China. She received her Ph.D. in Sociology (Demography and Advanced Quantitative Methods) from the University of Southern California, and was awarded the 2018 Alteryx Designer Advanced Certification.
Elan Rubinstein, Partner
Elan Rubinstein Pharm.D., MPH has over 30 years of experience in providing consulting related to: pharmacy benefits; marketing of pharmaceuticals, biotechnology and biological products; pharmaceuticals-related business strategy; new business development; pharmaceuticals-related new ventures. His consulting engagements typically involve market analysis; situation/opportunity assessment; market modeling; market positioning strategy; and new venture development. Clients have included manufacturers; disease carve-out companies; health plans; Centers for Medicare and Medicaid Services; PBMs; specialty pharmacies; employers; business coalitions; benefits consultants; futurists; entrepreneurs and venture capitalists.
Examples of consulting engagements: Dr. Rubinstein assisted CMS in developing pharmacy benefit policy for implementation of the Affordable Care Act. He developed product positioning strategies for an oncology biosimilar. He served as lead consultant to a pharmaceutical manufacturer in building an oncology disease management company, and co-managed that manufacturer’s community oncology advisory board. In favor of two specialty pharmacies, he prepared vendor proposals to CMS in response to two RFPs for the drug competitive acquisition program, and subsequently worked with CMS to address application questions/concerns.
Penelope K. Rossano, Partner
Penelope Rossano is an expert in international strategy. Her projects have included strategic, marketing, and financial analyses, mainly in the life sciences industry. During her 20+ years of professional experience, Penelope has conducted numerous studies and written business cases involving growth, organization and operations-related strategic issues. She has worked with clients ranging in size from start-ups to Fortune 500 companies and has covered a broad range of therapeutic areas including oncology, neurology, immunology, dermatology, hematology, diabetes, infectious disease, vaccines, and gene therapy.
Penelope has worked in investment banking, including Brown Brothers Harriman & Co., Commerzbank, and management consulting firms, including McKinsey, the Frankel Group and Blue Ridge Partners. Penelope served as Screening Committee Executive Officer for Mass Medical Angels, for which she managed the screening process for life sciences companies seeking angel funding. Penelope graduated from the University of Pennsylvania with two degrees – an MBA in Finance from The Wharton School of Business, and an MA in International Studies with a focus on Western Europe and the German Language and Culture from The Lauder Institute. She also graduated from the University of Cambridge with an M.Phil. in Biological Anthropology. Her undergraduate studies were completed at Harvard College. Penelope is holder of a Chartered Financial Analyst (CFA) charter and is fluent in German.
Xiang Jing Yao, Partner
Dr. Xiang Jing Yao is an internal medicine physician in Japan and serves as a guest professor for Oita University Faculty of Medicine. She specializes in regulatory affairs and drug development strategy. She has MD from Tokushima University Faculty of Medicine and PhD from Osaka University. After medical training at hospitals in Japan, she spent five years in research as a visiting fellow at NIA, NIDDK and NIH. She worked at Merck (NJ, US) for 11 years as a liaison in worldwide regulatory affairs department and successfully managed new drugs in various therapeutic areas including respiratory, metabolic disease, dermatology, etc. After Merck she returned to Japan and worked as a Specially Appointed Professor of Osaka University and managed new drug development programs in academia for 6 years, where she was a chief of the investigator initiated trials support office. In Osaka University her expertise broadly covered biologics, cardiovascular medicine, regenerative medicine.
Kunio Kageura, Partner
Kunio Kageura graduated from Hokkaido University in 1967 as Master of Pharmaceutical Sciences, and joined Clinical Research in MSD-Japan ( Merck’s subsidiary in Japan). In 1969, he started working as the head of the Project Planning & Management department. Over 37 years, he managed 18 development projects which Merck and/or Merck’s licensors conducted in Japan. During the period, he founded the “PP&M Forum in Japan” among foreign and domestic pharmaceutical firms in 1994. Because of MHLW’s ultimate acceptance of foreign clinical data in JNDAs, it has become very important for R&D departments in all of the pharmaceutical firms to run development projects as efficiently as possible, thereby minimizing a delay in launching new drugs in the Japanese market. Acting as the co-chairman of the forum, he played a leading part of the activities for 12 years until he retired from Merck in 2006. After retirement, he was appointed as the President of Biomedical Consulting International to provide technical and regulatory assistance to US/EU firms who intend to develop new drugs in Japan.
Experience Measured In Hard Outcomes
Years Of Applied Experience Used To Maximize The Probability Of Your Success